Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding ...

Our first biotech bi-weekly of 2026 is here with recent innovations in genomic drug discovery, organoid development and ADC ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

On the 12th (local time), the ‘JP Morgan Healthcare Conference’ opened in San Francisco, U.S. The biggest topic at this ...

Edesa Biotech, Inc. has announced its financial results for the first half of 2025, highlighting a $15 million equity financing aimed at advancing its vitiligo drug candidate, EB06, an anti-CXCL10 ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract Development and Manufacturing Organisations (CDMOs).

IO Biotech announced that it is on track to submit a Biologics License Application for its investigational cancer vaccine Cylembio® to the FDA by the end of 2025, following the completion of patient ...